home / stock / bioaf / bioaf news

BIOAF News and Press, Bioasis Technologies Inc From 08/09/21

Stock Information
Company Name: Bioasis Technologies Inc
Stock Symbol: BIOAF
Market: OTC
Website: bioasis.us
Menu
BIOAF BIOAF Quote BIOAF Short BIOAF News BIOAF Articles BIOAF Message Board
Get BIOAF Alerts

News, Short Squeeze, Breakout and More Instantly...
BIOAF - Bioasis Announces Allowance of Japanese Patent Application in Japan Relating to xB³(TM) Fusion Protein Comprising Iduronate-2-sulfatase

NEW HAVEN, Conn., Aug. 09, 2021 (GLOBE NEWSWIRE) -- BIOASIS TECHNOLOGIES INC . (TSXV:BTI; OTCQB:BIOAF), (the “Company” or “Bioasis”), a pre-clinical, research-stage biopharmaceutical company developing its proprietary xB 3 ™ platform te...
BIOAF - Bioasis Announces Filing of Its First Quarter Financial Statements and MD&A

NEW HAVEN, Conn., July 29, 2021 (GLOBE NEWSWIRE) -- Bioasis Technologies Inc. (TSX.V:BTI; OTCQB:BIOAF) (the “Company” or “Bioasis”), a pre-clinical, research-stage biopharmaceutical company developing its proprietary xB 3TM pla...

BIOAF - Bioasis Technologies Inc. Announces Stock Option Grants, Jeffrey Sprouse Appointed Preclinical Program Manager

NEW HAVEN, Conn., July 20, 2021 (GLOBE NEWSWIRE) -- BIOASIS TECHNOLOGIES INC . (TSXV:BTI; OTCQB:BIOAF), (the “Company” or “Bioasis”), a pre-clinical, research-stage biopharmaceutical company developing its proprietary xB 3 ™ platform te...

BIOAF - Bioasis Announces Positive Results From an Efficacy Study of xB3(TM)-IL-1RA in a Model of Multiple Sclerosis

NEW HAVEN, Conn., July 07, 2021 (GLOBE NEWSWIRE) -- BIOASIS TECHNOLOGIES INC . (TSXV:BTI; OTCQB:BIOAF), (the “Company” or “Bioasis”), a pre-clinical, research-stage biopharmaceutical company developing its proprietary xB 3 ™ platform te...
BIOAF - Bioasis Technologies appoints new finance chief

Bioasis Technologies (BIOAF) appoints of Dave Jenkins as CFO.Jenkins has previously worked at a number of technology and life sciences companies and brings diverse financial management experience in executing the strategic and financial plans of emerging companies.Press Release...

BIOAF - Bioasis Announces the Appointment of Dave Jenkins as Chief Financial Officer

NEW HAVEN, Conn., July 01, 2021 (GLOBE NEWSWIRE) -- BIOASIS TECHNOLOGIES INC . (TSXV:BTI; OTCQB:BIOAF), (the “Company” or “Bioasis”), a pre-clinical, research-stage biopharmaceutical company developing its proprietary xB 3 ™ platform te...

BIOAF - Bioasis Technologies Inc. and Oxyrane UK Ltd. enter into a Research Collaboration

NEW HAVEN, Conn. and MANCHESTER, United Kingdom, June 30, 2021 (GLOBE NEWSWIRE) -- Bioasis Technologies Inc. (TSXV:BTI; OTCQB:BIOAF) (“ Bioasis ”) and Oxyrane UK Ltd. ( “Oxyrane ”) are pleased to announce the initiation of a research colla...
BIOAF - Bioasis Technologies Announces Closing of Initial C$3,000,000 Funding by Lind Partners

NEW HAVEN, Conn., June 29, 2021 (GLOBE NEWSWIRE) -- Bioasis Technologies Inc. (“ Bioasis ” or the “ Company ”) (TSX.V:BTI; OTCQB:BIOAF), a pre-clinical, research-stage biopharmaceutical company developing its proprietary xB 3 TM platform t...

BIOAF - Bioasis Technologies jumps 23% on funding agreement of up to C$10M

A pre-clinical, research-stage biopharmaceutical company, Bioasis Technologies ([[BIOAF]] +23.3%) announces that it has entered into a convertible security funding agreement dated June 22, 2021 with Lind Global Macro Fund, LP, an entity managed by The Lind Partners.Under the te...

BIOAF - Bioasis Technologies enters into Convertible Security Funding Agreement for Institutional Investment of up to C$10 million

NEW HAVEN, Conn., June 22, 2021 (GLOBE NEWSWIRE) -- Bioasis Technologies Inc. (“ Bioasis ” or the “ Company ”) (TSX.V:BTI; OTCQB:BIOAF), a pre-clinical, research-stage biopharmaceutical company developing its proprietary xB 3 TM platform t...
Previous 10 Next 10